Home
News
- 1 BNGO stock annual price target is $17.70 which is 324.46% greater than its current trading price.
- 2 In a year, Bionano Genomics, Inc. stock lost 83.28% of its trading price.
- 3 BNGO stock prices were trading above a 20-day exponential moving average and below 50, 100, and 200-day EMA.
BNGO stock was trading above $14 but a constant shedding in the prices has troubled the investors as well as the trading prices. In a year, Bionano Genomics, Inc. stock lost 83.28% of its trading price.
BNGO Stock Price Analysis
The annual price target of BNGO stock is $17.70 which is 324.46% greater than its current trading price. Bionano Genomics, Inc. has a market capitalization of $127.001 Million and its share average trading volume of 819.197K.
At the time of publishing BNGO stock prices were trading above a 20-day exponential moving average and below 50, 100, and 200-day EMA. In the 52-week time frame stock’s highest trading price was $30.10 and its lowest traded at $2.95.
Since the past three trading sessions, buyers seem more active compared to sellers, which helped to pull BNGO stock 33.22% higher than its trading price. Starting from August 14 till August 30, Bionano stock seems to be consolidating below $4.
According to TradingView, 30.414 Million BNGO shares are free-floating, and the remaining 265.251k shares are closely held either by financial backers of the company or the board of members.
If buyers continue their dominance over sellers then there are possibilities that BNGO stock price might surge and face immediate resistance of $4.24 and following resistance of $5.99.
In different scenarios, if buyers fail to control sellers and trading volume, then BNGO stock will decline heavily and face immediate support of $3.67 and the next possible support of $3.10.
Financial Updates of Bionano Genomics, Inc.
In Q2 2023, Bionano Genomics, Inc. was expected to release $8.29 Million in revenue, impressing its investors the company reported 4.43% more revenue than the prediction.
The company reported $27.80 Million in revenue from which its gross profit was negative 10%, earnings before interest, taxes, depreciation, and amortization (EBITDA) was -430%, earnings before interest and taxes (EBIT) was -466% and net income was -477%.
The long-term assets of the company are $150.20 Million and the total liabilities of the company were $22.22 Million.
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection.
Technical Levels
Major Support: $3.67 and $3.10.
Major Resistance: $4.24 and $5.99.
Conclusion
At the time of publishing, BNGO stock prices were trading above a 20-day exponential moving average and below 50, 100, and 200-day EMA. There are still many chances that Bionano Genomics, Inc. stock might surge further and head towards its nearest resistance.
Disclaimer
The views and opinions stated by the author, or any people named in this article, are for informational ideas only and do not establish financial, investment, or other advice. Investing in or trading crypto or stock comes with a risk of financial loss.
Adarsh Singh is a true connoisseur of Defi and Blockchain technologies, who left his job at a “Big 4” multinational finance firm to pursue crypto and NFT trading full-time. He has a strong background in finance, with MBA from a prestigious B-school. He delves deep into these innovative fields, unraveling their intricacies. Uncovering hidden gems, be it coins, tokens or NFTs, is his expertise. NFTs drive deep interest for him, and his creative analysis of NFTs opens up engaging narratives. He strives to bring decentralized digital assets accessible to the masses.
